Literature DB >> 24467965

Mevalonate metabolism in cancer.

Georg Gruenbacher1, Martin Thurnher2.   

Abstract

Cancer cells are characterized by sustained proliferative signaling, insensitivity to growth suppressors and resistance to apoptosis as well as by replicative immortality, the capacity to induce angiogenesis and to perform invasive growth. Additional hallmarks of cancer cells include the reprogramming of energy metabolism as well as the ability to evade immune surveillance. The current review focuses on the metabolic reprogramming of cancer cells and on the immune system's capacity to detect such changes in cancer cell metabolism. Specifically, we focus on mevalonate metabolism, which is a target for drug and immune based cancer treatment.
Copyright © 2014 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Immune surveillance; Malignancy; Mevalonate; p53

Mesh:

Substances:

Year:  2014        PMID: 24467965     DOI: 10.1016/j.canlet.2014.01.013

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  20 in total

1.  Transcriptional Profiling Reveals a Common Metabolic Program in High-Risk Human Neuroblastoma and Mouse Neuroblastoma Sphere-Forming Cells.

Authors:  Mengling Liu; Yingfeng Xia; Jane Ding; Bingwei Ye; Erhu Zhao; Jeong-Hyeon Choi; Ahmet Alptekin; Chunhong Yan; Zheng Dong; Shuang Huang; Liqun Yang; Hongjuan Cui; Yunhong Zha; Han-Fei Ding
Journal:  Cell Rep       Date:  2016-10-04       Impact factor: 9.423

2.  Hypoxia-inducible factor 1α activates insulin-induced gene 2 (Insig-2) transcription for degradation of 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase in the liver.

Authors:  Seonghwan Hwang; Andrew D Nguyen; Youngah Jo; Luke J Engelking; James Brugarolas; Russell A DeBose-Boyd
Journal:  J Biol Chem       Date:  2017-04-17       Impact factor: 5.157

Review 3.  The interplay between cell signalling and the mevalonate pathway in cancer.

Authors:  Peter J Mullen; Rosemary Yu; Joseph Longo; Michael C Archer; Linda Z Penn
Journal:  Nat Rev Cancer       Date:  2016-08-26       Impact factor: 60.716

4.  Zoledronic acid causes γδ T cells to target monocytes and down-modulate inflammatory homing.

Authors:  Daniel W Fowler; John Copier; Angus G Dalgleish; Mark D Bodman-Smith
Journal:  Immunology       Date:  2014-12       Impact factor: 7.397

Review 5.  Mevalonate Metabolism in Immuno-Oncology.

Authors:  Georg Gruenbacher; Martin Thurnher
Journal:  Front Immunol       Date:  2017-12-01       Impact factor: 7.561

6.  Cilia loss sensitizes cells to transformation by activating the mevalonate pathway.

Authors:  Yue-Zhen Deng; Zhen Cai; Shuo Shi; Hao Jiang; Yu-Rong Shang; Ning Ma; Jing-Jing Wang; Dong-Xian Guan; Tian-Wei Chen; Ye-Fei Rong; Zhen-Yu Qian; Er-Bin Zhang; Dan Feng; Quan-Li Zhou; Yi-Nan Du; Dong-Ping Liu; Xing-Xu Huang; Lu-Ming Liu; Eugene Chin; Dang-Sheng Li; Xiao-Fan Wang; Xue-Li Zhang; Dong Xie
Journal:  J Exp Med       Date:  2017-12-13       Impact factor: 14.307

7.  Atorvastatin downregulates co-inhibitory receptor expression by targeting Ras-activated mTOR signalling.

Authors:  Isobel Okoye; Afshin Namdar; Lai Xu; Nicole Crux; Shokrollah Elahi
Journal:  Oncotarget       Date:  2017-09-18

Review 8.  Altered Mitochondrial Signalling and Metabolism in Cancer.

Authors:  Esita Chattopadhyay; Bidyut Roy
Journal:  Front Oncol       Date:  2017-03-20       Impact factor: 6.244

Review 9.  How to Hit Mesenchymal Stromal Cells and Make the Tumor Microenvironment Immunostimulant Rather Than Immunosuppressive.

Authors:  Alessandro Poggi; Serena Varesano; Maria Raffaella Zocchi
Journal:  Front Immunol       Date:  2018-02-19       Impact factor: 7.561

Review 10.  ABCA1, apoA-I, and BTN3A1: A Legitimate Ménage à Trois in Dendritic Cells.

Authors:  Chiara Riganti; Barbara Castella; Massimo Massaia
Journal:  Front Immunol       Date:  2018-06-08       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.